Advanced Therapies For Common Conditions In England Won’t Get Extra Funding, Says Ex-NICE Official

 
• By Eliza Slawther
  
NICE bases its payment modifiers on the intended patient population, not the therapy itself

More from Cell & Gene Therapies

More from Advanced Technologies